Dr Victoria Harle | Postdoctoral Fellow

Harle, Victoria

My projects focus upon trying to identify novel synthetically lethal targets within cancer cells. Synthetic lethality is the concept that the loss or disruption of two particular genes at the same time is lethal for a cell, whereas the loss of either one alone does not impact cell viability. This is something that can potentially be exploited in cancer therapies as multiple genes are often already altered in cancer cells. Indeed, there are examples of this approach been used successfully in the clinic, with the best-known example the use of PARP inhibitors in cancers lacking BRCA. We are currently undertaking multiple customized CRISPR-Cas9 screens with the aim of identifying new synthetically lethal gene targets.

Publications

  • Ubiquitin-specific protease 12 interacting partners Uaf-1 and WDR20 are potential therapeutic targets in prostate cancer.

    McClurg UL, Harle VJ, Nabbi A, Batalha-Pereira A, Walker S et al.

    Oncotarget 2015;6;35;37724-36

  • Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptor.

    Burska UL, Harle VJ, Coffey K, Darby S, Ramsey H et al.

    The Journal of biological chemistry 2013;288;45;32641-50

  • Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1.

    Patel R, Fleming J, Mui E, Loveridge C, Repiscak P et al.

    EMBO molecular medicine 2018;10;4

  • Deubiquitinating enzyme Usp12 regulates the interaction between the androgen receptor and the Akt pathway.

    McClurg UL, Summerscales EE, Harle VJ, Gaughan L and Robson CN

    Oncotarget 2014;5;16;7081-92

Harle, Victoria
Victoria's Timeline
2018

Joined the Wellcome Sanger Institute as a Postdoctoral Fellow

2015

Employed by the University of Glasgow at the CRUK Beatson Institute

Awarded PhD from Newcastle University

2011

Awarded MSci First Class (Hons) Biomedical Sciences from Newcastle University